• Trelagliptin Succinate Enhances Insulin Signaling in Adipocy

  2026-05-22

  The referenced study elucidates how trelagliptin succinate, a DPP-4 inhibitor, improves insulin resistance in adipocytes by modulating the PI-3K/AKT/GLUT4 pathway and reducing adverse adipokine secretion. This mechanistic insight supports better design of experiments targeting insulin signaling and phosphorylation dynamics in metabolic disease research.

• Deciphering Metabolite-Mediated Regulation of TET2 Dioxygena

  2026-05-22

  Zhang et al. establish a robust protocol combining biochemical assays with STD NMR to directly validate metabolite binding and regulatory effects on TET2 dioxygenase. This framework advances the study of metabolic-epigenetic interplay and enables precise identification of TET2 activators and inhibitors.

• PPARα-Driven TF Expression and Tumor Progression in pLELC

  2026-05-21

  This study uncovers how linoleic acid promotes tissue factor (TF) expression through PPARα activation, leading to enhanced tumor progression in primary pulmonary lymphoepithelioma-like carcinoma (pLELC). The findings highlight a mechanistic link between metabolic alterations, immune microenvironment modulation, and tumor biology, suggesting new therapeutic targets for this rare lung cancer subtype.

• Influenza Hemagglutinin (HA) Peptide: Precision in Ubiquitin

  2026-05-21

  Explore the advanced role of Influenza Hemagglutinin (HA) Peptide in ubiquitination research and protein-protein interaction assays. This in-depth guide reveals how HA tag peptides drive rigor and innovation in molecular biology workflows.

• Digoxin in Translational Research: Mechanism, Models & New F

  2026-05-20

  This thought-leadership article explores the evolving role of Digoxin, a potent Na+/K+ ATPase pump inhibitor, in both cardiovascular and antiviral translational research. Integrating mechanistic insight, animal model data, and strategic protocol guidance, the piece offers a roadmap for researchers seeking to harness Digoxin’s dual activity in arrhythmia, heart failure, and chikungunya virus inhibition. The discussion advances beyond conventional product profiles, highlighting workflow considerations, cross-domain opportunities, and the competitive research landscape.

• ARCA EGFP mRNA: Precision Controls and Assay Optimization Un

  2026-05-20

  Explore how ARCA EGFP mRNA enables quantitative optimization of fluorescence-based transfection assays in mammalian cells. This article reveals deeper scientific strategies for maximizing assay reproducibility and integrating pathway insights, setting it apart from prior overviews.

• Blue Light Damages Skin Barrier via EGFR/ERK/c-Jun Pathway

  2026-05-19

  This study demonstrates that repeated blue light exposure disrupts human and mouse skin barrier integrity through activation of the EGFR/ERK/c-Jun signaling pathway. The findings provide new mechanistic insight into visible light-induced skin damage, highlighting molecular targets for mitigation strategies.

• Dabigatran and Its Metabolite: Comparative Anticoagulant Eff

  2026-05-19

  This study rigorously demonstrates that dabigatran acylglucuronide, the main metabolite of dabigatran, displays a significantly weaker anticoagulant effect than the parent compound. The findings refine understanding of dabigatran’s pharmacodynamics and have direct implications for both laboratory assay design and clinical monitoring of anticoagulant status.

• Rotavirus Infection Suppresses Nrf2 Antioxidant Pathways via

  2026-05-18

  This study reveals that progressive rotavirus infection leads to a marked downregulation of the redox-sensitive transcription factor Nrf2 and its downstream antioxidant genes, mediated by enhanced ubiquitin-proteasome degradation. These findings deepen our understanding of host-pathogen interactions and highlight the complexity of cellular stress responses during viral infection.

• RAB31 Defines an ESCRT-Independent Exosome Biogenesis Pathwa

  2026-05-18

  Wei et al. (2021) identify RAB31 as a critical regulator marking and controlling a previously uncharacterized ESCRT-independent exosome pathway. This discovery refines the mechanistic understanding of exosome formation and secretion, highlighting the dual roles of RAB31 in ILV formation and preventing MVE degradation.

• Cimetidine: Distinct H2 Antagonist for Cancer & Barrier Mode

  2026-05-17

  Cimetidine is a histamine-2 receptor antagonist with partial agonist activity, enabling unique mechanistic insights in cancer and blood-brain barrier research. Its verified solubility and high purity underpin reproducible in vitro protocols. APExBIO’s Cimetidine (SKU B1557) offers researchers a robust tool for dissecting H2 receptor signaling and antitumor activity.

• Lyso-Tracker Red: Enhanced Lysosome Labeling in Live Cancer

  2026-05-16

  Lyso-Tracker Red enables robust, high-specificity visualization of lysosomal dynamics in live cells, surpassing older dyes in selectivity and workflow reliability. Its integration into apoptosis and methuosis research unlocks new insights into drug synergy and lysosomal membrane permeability in cancer studies.

• Ferrostatin-1: Mastering Ferroptosis for Translational Impac

  2026-05-15

  Explore how Ferrostatin-1 (Fer-1) empowers translational researchers to mechanistically dissect and strategically inhibit ferroptosis. This thought-leadership piece bridges experimental rigor, mechanistic insight, and competitive innovation, while contextualizing recent advances in redox-targeted cancer therapy.

• RBMS1 Depletion Enhances Anti-Tumor Immunity in TNBC via PD-

  2026-05-15

  This study identifies RBMS1 as a key post-transcriptional regulator of PD-L1 stability in triple-negative breast cancer (TNBC). By depleting RBMS1, the authors demonstrate enhanced anti-tumor immunity and improved efficacy of immune checkpoint blockade, providing a new avenue for immunotherapeutic strategies in immune-cold TNBC.

• Practical Guidance for Neuromedin S (rat) in GPCR Assays

  2026-05-14

  Neuromedin S (rat) provides a chemically defined, endogenous peptide agonist for reproducible activation of neuromedin U receptor signaling in controlled rat GPCR/G protein research. This product is intended solely for well-defined research protocols and should not be used in diagnostic, therapeutic, or clinical applications.

16653 records 1/1111 page Next 12345 下5页 Last page